Lupin secures place in Prestigious S&P Global Sustainability Yearbook 2025

Written by Ruchika Sharma Published On 2025-03-02T14:00:23+05:30 | Updated On 2 March 2025 2:00 PM IST

USFDA nod to Ipratropium Bromide Nasal Solution

Mumbai: Global pharma major Lupin Limited has announced its inclusion in prestigious S&P Global Sustainability Yearbook 2025, for the second consecutive year.

Lupin has been included in the Top 10% S&P Global CSA Score – which refers to companies that rank within the top 10% of their industry, based on their Corporate Sustainability Assessment (CSA) Score for 2024.

Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment (CSA) score. Lupin's S&P Global CSA score has significantly improved, from 65 to 75, in 2024. This year, 7,690 companies assessed in the 2024 CSA were considered for the 2025 Sustainability Yearbook, out of which only 780 companies across 62 industries were recognized.

Commenting on the achievement, Ramesh Swaminathan, Executive Director, Global CFO and Head – API Plus SBU, Lupin said, “Being featured in the S&P Global Sustainability Yearbook for the second consecutive year underscores our unwavering commitment to sustainability. We are at the forefront of the pharmaceutical industry in promoting sustainable business practices globally. We remain committed to advancing impactful initiatives that support a sustainable and equitable future for our patients, communities, and stakeholders worldwide.”

Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company has a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally.

Read also: USFDA completes inspection of Lupin Somerset facility with no observations

lupinlupin newsS and P Global Sustainability Yearbook 2025

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751